Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Cuba's informal market finds new space on growing internet
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Cuba's informal market finds new space on growing internet
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Cuba's informal market finds new space on growing internet
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Cuba's informal market finds new space on growing internet

COMPASS Pathways - CMPS Stock Forecast, Price & News

$10.05
-0.43 (-4.10%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.96
$10.72
50-Day Range
$8.96
$13.52
52-Week Range
$6.54
$34.79
Volume
99,054 shs
Average Volume
300,920 shs
Market Capitalization
$427.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.00

COMPASS Pathways MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
463.8% Upside
$56.67 Price Target
Short Interest
Bearish
9.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.04) to ($2.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

883rd out of 1,044 stocks

Pharmaceutical Preparations Industry

429th out of 510 stocks

CMPS stock logo

About COMPASS Pathways (NASDAQ:CMPS) Stock

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Receive CMPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter.

CMPS Stock News Headlines

Compass Pathways: Q3 Earnings Insights
Compass Pathways's Earnings Outlook
Is Now a Good Time to Invest In Psychedelics Stocks?
CMPS COMPASS Pathways plc
COMPASS Pathways And The Trillion Dollar Opportunity
See More Headlines
Receive CMPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter.

CMPS Company Calendar

Last Earnings
11/03/2022
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CMPS
Fax
N/A
Employees
116
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$56.67
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+337.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-71,740,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.57 per share

Miscellaneous

Free Float
31,997,000
Market Cap
$427.93 million
Optionable
Not Optionable
Beta
2.32

Key Executives

  • Mr. George Jay Goldsmith (Age 68)
    Exec. Chairman & Co-Founder
    Comp: $943.52k
  • Dr. Ekaterina Malievskaia M.D. (Age 55)
    Co-Founder, Chief Innovation Officer & Exec. Director
    Comp: $669.13k
  • Dr. Guy Goodwin
    Chief Medical Officer
  • Mr. Kabir Nath M.A.
    M.B.A., Chief Exec. Officer
  • Mr. Michael F. Falvey (Age 63)
    Chief Financial Officer
  • Dr. Greg Ryslik Ph.D.
    Exec. VP of AI, Engineering, Digital Health Research & Technology
  • Mr. Stephen D. Schultz
    Sr. VP of Investor Relations
  • Mr. Matthew Owens
    Gen. Counsel & Chief Legal Officer
  • Ms. Anne Benedict
    Chief People Officer
  • Mr. Lars Christian Wilde (Age 37)
    Sr. Advisor













CMPS Stock - Frequently Asked Questions

Should I buy or sell COMPASS Pathways stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CMPS shares.
View CMPS analyst ratings
or view top-rated stocks.

What is COMPASS Pathways' stock price forecast for 2023?

4 brokerages have issued 1 year price targets for COMPASS Pathways' stock. Their CMPS share price forecasts range from $34.00 to $120.00. On average, they anticipate the company's stock price to reach $56.67 in the next year. This suggests a possible upside of 463.8% from the stock's current price.
View analysts price targets for CMPS
or view top-rated stocks among Wall Street analysts.

How have CMPS shares performed in 2022?

COMPASS Pathways' stock was trading at $22.10 on January 1st, 2022. Since then, CMPS shares have decreased by 54.5% and is now trading at $10.05.
View the best growth stocks for 2022 here
.

When is COMPASS Pathways' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our CMPS earnings forecast
.

How were COMPASS Pathways' earnings last quarter?

COMPASS Pathways plc (NASDAQ:CMPS) announced its earnings results on Thursday, November, 3rd. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.23.

What other stocks do shareholders of COMPASS Pathways own?

Based on aggregate information from My MarketBeat watchlists, some companies that other COMPASS Pathways investors own include Nikola (NKLA), Vaxart (VXRT), Beyond Meat (BYND), Evofem Biosciences (EVFM), GrowGeneration (GRWG), McDonald's (MCD), Plug Power (PLUG), Block (SQ), Workhorse Group (WKHS) and

When did COMPASS Pathways IPO?

(CMPS) raised $100 million in an IPO on Friday, September 18th 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is COMPASS Pathways' stock symbol?

COMPASS Pathways trades on the NASDAQ under the ticker symbol "CMPS."

Who are COMPASS Pathways' major shareholders?

COMPASS Pathways' stock is owned by many different institutional and retail investors. Top institutional shareholders include Logos Global Management LP (1.20%), PFM Health Sciences LP (0.93%), ARK Investment Management LLC (0.91%), Sumitomo Mitsui Trust Holdings Inc. (0.81%), BlackRock Inc. (0.61%) and Barclays PLC (0.61%). Insiders that own company stock include David Y Norton and Ekaterina Malievskaia.
View institutional ownership trends
.

How do I buy shares of COMPASS Pathways?

Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is COMPASS Pathways' stock price today?

One share of CMPS stock can currently be purchased for approximately $10.05.

How much money does COMPASS Pathways make?

COMPASS Pathways (NASDAQ:CMPS) has a market capitalization of $427.93 million. The company earns $-71,740,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis.

How many employees does COMPASS Pathways have?

The company employs 116 workers across the globe.

How can I contact COMPASS Pathways?

The official website for the company is www.compasspathways.com. The company can be reached via phone at 1-646-905-3974 or via email at ir@compasspathways.com.

This page (NASDAQ:CMPS) was last updated on 11/27/2022 by MarketBeat.com Staff